Swedish Orphan Biovitrum

Swedish Orphan Biovitrum (Sobi) tops Q1 expectations with double‑digit haemophilia and immunology growth, strong EBITDA, and a solid pipeline for future earnings momentum.

Nordea boosts Sobi’s target price, citing a $300‑$400 M rare‑disease pipeline and new board confidence, while Ionis cuts prices to support shared access and growth.

Swedish Orphan Biovitrum’s Aspaveli gains EU approval, boosting sales guidance and brokerage upside as the company expands its rare‑kidney drug portfolio.